¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cell growth"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • clear cell
    Åõ¸í¼¼Æ÷
  • clear cell acanthoma
    Åõ¸í¼¼Æ÷°¡½Ã¼¼Æ÷Á¾, Åõ¸í¼¼Æ÷±Ø¼¼Æ÷Á¾
  • clear cell adenocarcinoma
    Åõ¸í¼¼Æ÷»ù¾ÏÁ¾, Åõ¸í¼¼Æ÷¼±¾ÏÁ¾
  • clear cell carcinoma
    Åõ¸í¼¼Æ÷¾ÏÁ¾
  • clear cell hidradenoma
    Åõ¸í¼¼Æ÷¶¡»ùÁ¾
  • clear cell sarcoma
    Åõ¸í¼¼Æ÷À°Á¾
  • columnar cell
    ¿øÁÖ¼¼Æ÷
  • committed cell
    ¾ô¸Ç¼¼Æ÷, ¼öÀÓ¼¼Æ÷
  • complex cell
    º¹ÇÕ¼¼Æ÷
  • cone cell
    ¿ø»Ô¼¼Æ÷
  • cone cell layer
    ¿ø»Ô¼¼Æ÷Ãþ, ¿øÃß¼¼Æ÷Ãþ
  • connective tissue cell
    °áÇÕÁ¶Á÷¼¼Æ÷
  • continuous cell line
    ¹«ÇÑÁõ½Ä¼¼Æ÷ÁÖ, ¿¬¼Ó°è´ë¼¼Æ÷ÁÖ
  • contractile fiber cell
    ¼öÃ༶À¯¼¼Æ÷
  • cover cell
    µ¤°³¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basophilic cell
    È£¿°±â¼¼Æ÷
  • basosquamous cell carcinoma
    ¹Ù´ÚÆíÆò¼¼Æ÷¾ÏÁ¾, ±âÀúÆíÆò¼¼Æ÷¾ÏÁ¾
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • blood cell separator
    Ç÷±¸ºÐ¸®±â
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • border cell
    °æ°è¼¼Æ÷, ¼Ó°æ°è¼¼Æ÷
  • bristle cell
    ¾ï¼¾Åм¼Æ÷, °­¸ð¼¼Æ÷
  • burr cell
    ¹«µòÅ鳯ÀûÇ÷±¸
  • cell bank
    ¼¼Æ÷ÀºÇà
  • nerve cell body
    ½Å°æ¼¼Æ÷ü
  • cell
    ¼¼Æ÷
  • cell culture
    ¼¼Æ÷¹è¾ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Graham cell
    ±×¶óÇÔ¼¼Æ÷
  • Granulosa cell
    °ú¸³¸·¼¼Æ÷(Î¨Ø£Ø¯á¬øà)
  • Granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç(Î¨Ø£Ø¯á¬øàðþåË)
  • H-9 cell line
    H-9 ¼¼Æ÷°è
  • HeLa cell
    Çï¶ó¼¼Æ÷.
  • HeLa cell
    Çï¶ó¼¼Æ÷
  • Heidenhain s cell
    ÇÏÀ̵§ÇÏÀμ¼Æ÷.
  • Henle s cell
    Çî·¯¼¼Æ÷.
  • Hfr cell
    °íºóµµÀçÁ¶ÇÕ¼¼Æ÷
  • Hulle cell
    ¿ÜÇǼ¼Æ÷
  • ICSH = interstitial cell stimulating hormone
    °£Áú¼¼Æ÷ÀÚ±Ø(Êàòõá¬øàí©Ð½)È£¸£¸ó.
  • ICSH=£¾interstitial cell stimulating hormone
    °£Áú¼¼Æ÷ÀÚ±ØÈ£¸£¸ó.
  • K cell
    K¼¼Æ÷, »ìÇØ¼¼Æ÷
  • LE cell
    LE¼¼Æ÷.
  • LE cell phenomenon
    LE¼¼Æ÷Çö»ó.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • macrophage,macrophage derived growth factor
    ´ë½Ä¼¼Æ÷±â¿ø ¼ºÀåÀÎÀÚ(¡­ÑÃê¹ à÷íþì×í­)
  • maximal growth rate
    ÃÖ´ëÁõ½ÄÀ²
  • maximum stationary phase (of growth)
    (Áõ½Ä)±Ø´ëÁ¤Áö±â(ñòãÖпÓÞïÎò­Ñ¢).
  • membranous bone growth
    ¸·»ó°ñ ¼ºÀå(دßÒÍéà÷íþ).
  • membranous bone growth
    ¸·»ó°ñ¼ºÀå(¡­ßÒÍéà÷íþ)
  • new growth
    ½Å»ý¼º.(º´¸®)½Å»ý¹°(ãæßæÚª).
  • new growth
    ½Å»ý¼º(ãæßæàõ).½Å»ý¹°(ãæßæÚª)
  • occupational growth
    Á÷¾÷Àû ¼ºÀå (ÊÙËøËÛËö).
  • one step growth
    ÀÏ´ÜÁõ½Ä(ìéÓ«ñòãÖ).
  • one step growth curve
    ÀÏ´ÜÁõ½Ä°î¼±(¡­ÍØàÊ).
  • one step growth experiment
    ÀÏ´ÜÁõ½Ä½ÇÇè(¡­ãùúÐ).
  • organotypic growth
    ±â°üÇüÀû ¼ºÀå(ÐïίúþîÜà÷íþ)
  • pathologic growth
    º´Àû¼ºÀå(Ü»îÜà÷íþ)
  • phase, growth
    Áõ½Ä±â
  • physical growth
    ½Åü¹ßÀ°(ãóô÷Û¡ëÀ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Satellite cell
    ½Å°æÀý¾Æ±³¼¼Æ÷ [À§¼º¼¼Æ÷]
    [¿¾ ¿ë¾î] À§¼º¼¼Æ÷
  • Cardiac muscle cell
    ½ÉÀå±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ½É±Ù¼¼Æ÷
  • Glial cell
    ¾Æ±³¼¼Æ÷
    [¿¾ ¿ë¾î] ±³¼¼Æ÷
  • Glial cell process
    ¾Æ±³¼¼Æ÷µ¹±â
    [¿¾ ¿ë¾î] ±³¼¼Æ÷µ¹±â
  • Glial cell body
    ¾Æ±³¼¼Æ÷ü
    [¿¾ ¿ë¾î] ±³¼¼Æ÷ü
  • Ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¾Æ¸Þ¹Ù¾ç¼¼Æ÷
  • Dark cell
    ¾îµÎ¿î¼¼Æ÷
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷
  • Dark cell
    ¾îµÎ¿î¼¼Æ÷
    [¿¾ ¿ë¾î] ¾ÏÁÖ¼¼Æ÷
  • Trophoblastic giant cell
    ¿µ¾ç¸·°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] °Å´ë¿µ¾ç¸·¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø±âÁ¾(¹è)¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø±âÁ¾¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
  • Columnar ependymal cell
    ¿øÁÖ³ú½Ç¸·¼¼Æ÷
    [¿¾ ¿ë¾î] ¿øÁÖ»óÀǼ¼Æ÷
  • Columnar epithelial cell
    ¿øÁÖ»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¿øÁÖ»óÇǼ¼Æ÷
  • Columnar cell
    ¿øÁÖ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿øÁÖ¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • plaque forming cell
    ÇöóÅ© Çü¼º ¼¼Æ÷(û¡à÷á¬øà)
  • plasma cell
    ÇüÁú¼¼Æ÷(û¡òõá¬øà)
  • primed cell
    °¨ÀÛ¼¼Æ÷(ÊïíÂá¬øà)
  • productive cell
    »ý»ê ¼¼Æ÷(ßæß§á¬øà)
  • red cell agglutination
    ÀûÇ÷±¸ ÀÀÁý(îåúìϹëêó¢)
  • red cell lysis
    ÀûÇ÷±¸ ¿ëÇØ(îåúìϹéÁú°)
  • regulated secretory cell
    ÇÇÁ¶Àý(ù¬ðàï½) ºÐºñ¼¼Æ÷(ÝÂÝôá¬øà)
  • resting cell
    È޽O÷(ýÌãÓá¬øà)
  • restrictive cell
    Á¦ÇÑ ¼¼Æ÷(á¬øà)
  • sector cell
    ¼½ÅͽÇ(ãø)
  • separation cell
    ºÐ¸®½Ç(ÝÂ×îãø)
  • sickle cell
    ³´¼¼Æ÷(á¬øà)
  • sickle cell anemia
    ³´¼¼Æ÷(á¬øà)ºóÇ÷(Þ¸úì)
  • sickle cell disease
    ³´¼¼Æ÷(á¬øà)Áúȯ(òðü´)
  • sickle cell hemoglobin
    ³´¼¼Æ÷(á¬øà)È÷¸ð±Û·Îºó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
TCGF T-cell growth factor
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
NK cell Natural Killer cell
RS cell Reed Sternberg cell
Tc cell cytotoxic T cell
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
bFGF Basic Fibroblastic Growth Factor
basic FGF Basic fibroblast growth factor
beta NGF Beta nerve growth factor
NGF Beta-nerve growth factor
bGH Bovine growth hormone
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell enclosure
    ¼¼Æ÷ ºÀÀÔü
    ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ ¼¼Æ÷³»¿¡ ±èÀÚ ¾× µî¿¡ ÀÇÇØ ¿°»öµÈ °ú¸³»ó ¶Ç´Â ±× ¹ÛÀÇ Æ¯Â¡ÀÌ ÀÖ´Â ÇüŸ¦ º¸ÀÌ´Â ¼Òü. °£´ÜÈ÷ ºÀÀÔü¶ó°íµµ ÇÑ´Ù. ±¤°ßº´ µî ¹ÙÀÌ·¯½º º´À» Áø´ÜÇÏ´Â µ¥ ÀÌ¿ëµÇ´Â ¼¼Æ÷ ºÀÀÔüÀÇ º»·¡ ÇüÅ¿¡ °üÇÑ ³íÀǰ¡ ¸¹¾ÒÀ¸³ª, Áö±ÝÀº ¹ÙÀÌ·¯½º º´ÀÇ º´¿øÃ¼ÀÓÀÌ È®ÀεǾú´Ù. ¼¼Æ÷ ºÀÀÔü¿¡´Â ¼¼Æ÷Áú³» ºÀÀÔü¿Í ¼¼Æ÷ÇÙ³» ºÀÀÔü°¡ ÀÖ´Ù. ¼¼Æ÷Áú³» ºÀÀÔü¿¡´Â õ¿¬µÎ, ¿ìµÎÀÇ °¡¸£´Ï¿¡¸® ¼Òü, ±¤°ßº´ÀÇ ³×±×¸® ¼Òü µîÀÌ ÀÖ´Ù. À̵éÀº È£»ê¼º, ¿øÇü, ±ÕÁú ¶Ç´Â °ú¸³»ó ±¸Á¶¸¦ °¡Áø °Í°ú Æ®¶óÄÚ¸¶ÀÇ ÇÁ·Î¹Ùüũ ¼Òü µî È£¿°±â¼ºÀ¸·Î º¹ÀâÇÑ ÇüÀ» °¡Áø °ÍÀÌ ÀÖ´Ù. ¼¼Æ÷ÇÙ³» ºÀÀÔü¿¡´Â Ç츣Æä½º À¯¹ß ¹ÙÀÌ·¯½º·Î Çü¼ºµÈ ºÀÀÔü°¡ ÀÖ´Ù. ¼¼Æ÷ ºÀÀÔü¸¦ ÇÔÀ¯ ³»¿ë¹°¿¡ µû¶ó ºÐ·ùÇϸé, ¹ÙÀÌ·¯½º°¡ ¸ðÀÎ °Í°ú ¹ÙÀÌ·¯½º ±¸¼º ¹°Áú·Î µÈ °ÍÀÌ ¸ðÀÎ °Í, ±×¸®°í ¹ÙÀÌ·¯½ºÀÇ ¼ººÐ°ú °ü·ÃÀÌ ¾ø´Â ƯÀ¯ÇÑ ´Ü¹éÁú·Î ÀÌ·ç¾îÁø °Í µî 3Á¾·ù·Î ³ª´¶´Ù. ¼¼Æ÷ ºÀÀÔüÀÇ Çü¼ºÀº ÁÖ·Î ¹ÙÀÌ·¯½ºÀÇ °¨¿°°ú °ü·ÃµÇ³ª À̿ܿ¡µµ Áß±Ý¼Ó µîÀÇ ¾àǰ Åõ¿©³ª ¼¼Æ÷´ë»ç Àå¾Ö¸¦ ÀÏÀ¸Å°´Â °Í¿¡ ÀÇÇÏ¿© ³ªÅ¸³ª±âµµ ÇÑ´Ù. ¿¹¸¦ µé¸é, ÁßÃ߽Űæ°èÀÇ ÁúȯÀÎ ÆÄŲ½¼ º´ÀÇ °æ¿ì ½Å°æ¼¼Æ÷³»¿¡¼­ ·¹ºß ¼Òü¶ó´Â ¼Òü¸¦, ¹Ì¿ÀŬ·Î´©½º °£Áú ȯÀÚÀÇ ³ú³ª ô¼öÀÇ ½Å°æ¼¼Æ÷³»¿¡¼­´Â ¹Ì¿ÀŬ·Î´©½º ¼Òü¸¦ º¼ ¼ö Àִµ¥ À̵éÀº ¸ðµÎ ¼¼Æ÷Áú³» ºÀÀÔüÀÌ´Ù.
  • cell fusion
    ¼¼Æ÷ ÀÀÇÕ, ¼¼Æ÷ À¶ÇÕ
    µÎ Á¾·ù ÀÌ»óÀÇ ¼¼Æ÷¸¦ ¹ÙÀÌ·¯½º,
  • cell harverter
    ¼¼Æ÷ ȸ¼ö±â
    ´Ù¼öÀÇ ¼¼Æ÷ ¹è¾ç ¿ë±â¿¡¼­ µ¿½Ã¿¡ ¹è¾çµÈ ´É·üÀÌ ÁÁÀº ¼¼Æ÷¸¦ äÃëÇÏ´Â ±â±âÀÇ ÃÑĪ.
  • cell hybridization
    ¼¼Æ÷ ÇÏÀ̺긮µå Çü¼º
  • cell injury
    ¼¼Æ÷ ¼Õ»ó
  • cell interface
    ¼¼Æ÷ »çÀÌ ¸é, ¼¼Æ÷ °£¸é
  • cell kinetics
    ¼¼Æ÷ ¿ªÇÐ
  • cell lethality
    ¼¼Æ÷ Ä¡»çÀ²
  • cell line
    ¼¼Æ÷°è
  • cell mass
    ¿ø±â ¼¼Æ÷±º
  • cell mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª ÀÛ¿ë, ¼¼Æ÷¼º ¸é¿ª
    Ç׿øÀÌ T Àӯı¸¸¦ ÀÚ±ØÇÏ¸é ¸é¿ª ±Û·ÎºÒ¸°À» ÇÕ¼º ºÐºñÇÏ´Â °ÍÀÌ ¾Æ´Ï°í Àӯı¸ ÀÚ½ÅÀÌ Ç×ü·Î ÀÛ¿ëÇÏ´Â °¨ÀÛ Àӯı¸°¡ µÇ´Â °ÍÀÌ Ã¼¾×¼º ¸é¿ª°úÀÇ Â÷ÀÌ·Î, ü¾×¼º ¸é¿ªÀÌ ÁÖ·Î ±Þ¼º ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀε¥ ºñÇØ¼­ ¼¼Æ÷¼º ¸é¿ªÀº ¸¸¼º ¼¼±Õ¼º Áúȯ, Á¶Á÷ À̽Ä, ¾Ï ¼¼Æ÷, °õÆÎÀÌ Áúȯ, ƯÈ÷ ¹ÙÀÌ·¯½º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀÌ´Ù.
  • cell mediated lympholysis
    ¼¼Æ÷ ¸Å°³ ¸²ÇÁ±¸ ¿ëÇØ
  • cell mediated reaction
    ¼¼Æ÷ ¸Å°³¼º ¹ÝÀÀ
  • cell membrane permeability
    ¼¼Æ÷¸· Åõ°ú¼º
  • cell of parathyroid gland
    ºÎ°©»ó»ù ¼¼Æ÷, ºÎ°©»ó¼± ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
endothelial growth factors These growth factors are soluble mitogens secreted by a variety of organs. The factors are a mixture of two single chain polypeptides which have affinity to heparin. Their molecular weight are organ and species dependent. They have mitogenic and chemotactic effects and can stimulate endothelial cells to grow and synthesise DNA. The factors are related to both the basic and acidic fibroblast growth factors but have different amino acid sequences.
(12 Dec 1998)
endothelium-derived growth factor synthase <enzyme> Converts l-arginine to a smooth muscle relaxing factor and stimulates the formation of cyclic-GMP
Registry number: EC 1.5.1.-
Synonym: edrf synthase
(26 Jun 1999)
epidermal growth factor <growth factor> A mitogenic polypeptide initially isolated from male mouse submaxillary gland.
The name refers to the early bioassay, but epidermal growth factor is active on a variety of cell types, especially but not exclusively epithelial. Human equivalent originally named urogastrone owing to its hormone activity.
Acronym: EGF
(18 Nov 1997)
epidermal growth factor receptor protein-tyrosine kinase <enzyme> The catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of epidermal growth factor receptor.
Registry number: EC 2.7.1.-
(12 Dec 1998)
epidermal growth factor-urogastrone <chemical> Single chain, nonhelical, acidic polypeptides of about 52 amino acids found in most mammals. Epidermal growth factor and urogastrone are not identical but seem to share biological acivities. They promote growth of, and cell proliferation in, certain tissues, especially epidermal structures and inhibit acid secretion by the stomach. They have been used to treat gastrointestinal ulcers.
Chemical name: Epidermal growth factor
(12 Dec 1998)
excess annual growth The amount by which new forest growth exceeds removal in a year. The annual quantity of wood produced in a forest in excess of market demand.
(05 Dec 1998)
exponential growth <biology> A rate of growth of an organism, a part of an organism, or a population of organisms which, when graphed, produces an exponential or logarithmic curve. Such a rate occurs, for example: during the exponential growth phase, when a population of bacterial (or other) cells divide at a constant rate so that the total number of cells doubles with each division.
(09 Oct 1997)
keratinocyte growth factor <growth factor> A growth factor structurally related to fibroblast growth factor.
(18 Nov 1997)
urban growth boundary A land use boundary surrounding a city. Urban land uses are permitted within the urban growth boundary.
(05 Dec 1998)
fibroblast growth factor <growth factor> Acidic fibroblast growth factor (alpha FGF, HBGF 1) and basic FGF (beta FGF, HBGF 2) are the two founder members of a family of structurally related growth factors for mesodermal or neuroectodermal cells.
Synonym: heparin binding growth factor.
Acronym: FGF
(18 Nov 1997)
fibroblast growth factor, acidic <chemical> A growth factor which has been isolated from a variety of cells. It contains 154 amino acid residues and has potent heparin-binding activity. Heparin potentiates the biological activities of afgf. The growth factor is an extremely potent inducer of DNA synthesis in a variety of normal diploid mammalian cell types from mesoderm and neuroectoderm lineages and also has chemotactic and mitogenic activities.
Chemical name: Fibroblast growth factor (human brain acidic protein moiety reduced)
(12 Dec 1998)
fibroblast growth factor, basic A single-chain polypeptide of approximately 15-16 kD which has been isolated from a variety of cells. It has a 55% amino acid residue identity to acidic fibroblast growth factor and has potent heparin-binding activity. However, in contrast to the acidic fibroblast growth factor, heparin does not potentiate the biological activities of bfgf. The growth factor is an extremely potent inducer of DNA synthesis in a variety of normal diploid mammalian cell types from mesoderm and neuroectoderm lineages and promotes cellular differentiation in vitro.
(12 Dec 1998)
fibroblast growth factor receptor Family of receptor tyrosine kinases for fibroblast growth factor.
(18 Nov 1997)
fibroblast growth factor receptor-like embryonic kinase <enzyme> Found in avian embryonic tissue; involved in early differentiation of skeletal muscle.
Registry number: EC 2.7.1.-
Synonym: frek
(26 Jun 1999)
foetal growth retardation The failure of a foetus to maintain its expected growth potential at any gestational stage.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á